Standalone Diabetes Care business expected to leverage position as global leader in insulin delivery and expand presence in large and high-growth diabetes market - Spinoff allows both BD and NewCo to enhance each company's focus on meeting the needs of their respective patients, customers and

- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. - BD's COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. - BD's core growth led by strong growth in Medication

FRANKLIN LAKES, N.J. , April 29, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor healthcare conferences during the month of May:     The Bank of

FRANKLIN LAKES, N.J. , April 29, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV.

John DeFord to join newly formed external Scientific Advisory Board FRANKLIN LAKES, N.J. , April 28, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president

FRANKLIN LAKES, N.J. , April 27, 2021 /PRNewswire/ -- The Board of Directors of BD ( Becton, Dickinson and Company ) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021 .